EACS2023: 335 Weight and Body mass index gain among people living with HIV-1 switching to a single tablet of bictegravir /emtricitabine/tenofovir alafenamide L. Buzón , J. Troya , G. Pousada , R. Micán , C. Galera , J. Sanz , I. Santos , C. Dueñas , N. Cabello , C. Martín , M.J. Galindo , M.Á. Garcinuño , D. Ortega , R. Pedrero-Tomé , RETROBIC Hospital de Burgos, Burgos, Spain, Hospital Universitario Infanta Leonor, Madrid, Spain, Hospital Álvaro Cunqueiro, Vigo, Spain, Hospital Universitario La Paz, Madrid, Spain, Hospital L´Arrixaca Murcia, Murcia, Spain, Hospital Príncipe de Asturias, Madrid, Spain, Hospital Universitario La Princesa, CIBERINFEC Instituto de Salud Carlos III, Madrid, Spain, Hospital de Valladolid, Valladolid, Spain, Hospital Clínico de Madrid, Madrid, Spain, Complejo Asistencial de Zamora, Zamora, Spain, Hospital Clínico de Valencia, Valencia, Spain, Complejo Asistencial de Ávila, Ávila, Spain, Fundación de Investigación e Innovación del Hospital Universitario Infanta Leonor y del Sureste, Madrid, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Recent evidence suggests that integrase strand transfer inhibitors are associated with body mass index increase and weight gain in people living with VIH-1 (PLWH). Naïve and switching strategies with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) have become a gold standard. However, data on weight and body mass index (BMI) gain in big real-life cohorts of long-term treated patients switching to B/F/TAF are scarce. Method: We performed a multicenter, non-controlled, retrospective study of pretreated and suppressed PLH switching to B/F/TAF. This study evaluated body mass index (BMI) and weight changes in PLH in weeks 24, 48, and 48 after switching to a single tablet of B/F/TAF. Results: The study comprised 1515 persons from 13 hospitals in Spain, of whom 80.0% were men and had a median age of 51.0 [42.0 – 57.0] years. The median time of HIV infection was 18.0 [10.0–27.0] years. AIDS diagnoses were made in 22.4% of cases. Across the entire sample, patients gain on average 0.8 [-0.7 – 3.0] kg at 24 weeks (p = 0.034); 1.6 [-1.0 – 4.3] kg at 48 weeks (p < 0.001) and 2.9 [-0.5 – 6.8] kg at 96 weeks (p < 0.001). This weight gain translates into a significative increase in BMI with respect to a basal value of 24.9 of 0.6, 0.7, and 1.4, respectively (p < 0.001). The prevalence of excess weight is observed to increase from 48.6% in baseline data to 59.2% at week 96 (p < 0.001. No significant differences were observed in weight gain by sex, age groups, and the presence of comorbidities. Conclusions: In patients with HIV-controlled infection, switching to B/F/TAF was associated with a median increase in weight of 1.45 kg/year and 0.7 in BMI. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 12 4 13 1 2 3 4 5 6 7 8 9 10 11 12 13 103
RkJQdWJsaXNoZXIy Mzc2ODc=